ZBIO
Zenas BioPharma, Inc.Company Information
- Company Name
- Zenas BioPharma, Inc.
- CIK
- CIK0001953926
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ZBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ZBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-18
- Last sale
- —
- Shares purchased (TTM)
- 1,282,683
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 57,627,619
- Shares outstanding
- 63,112,314
- Ownership
- 91.31%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 12.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||
| Series A Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Current | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 197 | 500 | 111 | 116 | 44 | 197 | 320 | 360 | ||||||
| Series B Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
| Short Term Investments | 447 | 217 | 233 | 175 | 229 | 116 | 31 | 27 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 11 | 13 | 8 | 6 | 5 | 5 | 5 | 7 | ||||||
| Assets Current | 654 | 730 | 351 | 297 | 279 | 318 | 356 | 394 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | 0 | ||||||
| Long Term Investments | 31 | 1 | 17 | 11 | 2 | 2 | - | - | ||||||
| Other Assets Noncurrent | 16 | 15 | 14 | 14 | 12 | 13 | 13 | 9 | ||||||
| Assets | 702 | 748 | 384 | 322 | 293 | 334 | 370 | 403 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable Current | 8 | 9 | 7 | 6 | 8 | 20 | 17 | 15 | ||||||
| Accrued Liabilities Current | 57 | 51 | 54 | 45 | 45 | 28 | 39 | 29 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities Current | 66 | 61 | 63 | 52 | 53 | 49 | 57 | 44 | ||||||
Liabilities Noncurrent | ||||||||||||||
| Long Term Debt Noncurrent | - | - | 79 | 73 | - | - | - | - | ||||||
| Secured Long Term Debt | 74 | 72 | - | - | - | - | - | - | ||||||
| Long Term Notes Payable | 223 | 194 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Noncurrent | 389 | 351 | 79 | 73 | - | - | 0 | - | ||||||
| Liabilities | 455 | 412 | 141 | 126 | 53 | 49 | 58 | 44 | ||||||
Stockholders Equity | ||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | ||||||||||||||
| Additional Paid In Capital | 1,206 | 1,182 | 1,007 | 721 | 713 | 705 | 700 | 694 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -958 | -846 | -765 | -525 | -473 | -421 | -387 | -335 | ||||||
| Stockholders Equity | 247 | 336 | 242 | 196 | 240 | 284 | 312 | 359 | ||||||
| Liabilities And Stockholders Equity | 702 | 748 | 384 | 322 | 293 | 334 | 370 | 403 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Series Seed Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Authorized | 175 | 175 | 175 | 175 | 175 | 175 | 175 | 175 | ||||||
| Common Stock Shares Issued | 63 | 62 | 54 | 42 | 42 | 42 | 42 | 42 | ||||||
| Related Party | - | - | - | - | - | - | 0 | 0 | ||||||
| Shares Outstanding | 63 | 62 | 54 | 42 | 42 | 42 | 42 | 42 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZenas BioPharma, Inc. (ZBIO) — SEC Financial Statements & Analysis
Zenas BioPharma, Inc. (ZBIO) is a pharmaceutical preparations company, incorporated in DE. Zenas BioPharma, Inc. trades on Nasdaq as: ZBIO. Zenas BioPharma, Inc. (ZBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Zenas BioPharma, Inc. carries a market cap of $1.60B, a P/E ratio of -3.31x, a P/B ratio of 6.48x, a P/S ratio of 1601.79x, an enterprise value of $1.70B, and an EV/EBITDA multiple of -3.58x. On profitability, it posts an operating margin of -47557.30%, a net margin of -48438.40%, a Return on Equity (ROE) of -199.04%, a Return on Assets (ROA) of -97.39%, and a Return on Invested Capital (ROIC) of -175.01%. Per share, it reports EPS of $-7.67, diluted EPS of $-7.67, free cash flow per share of $-3.58, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -93.33% year-over-year, net income growth of 99.51% year-over-year, and EPS growth of 32.35% year-over-year. On the balance sheet, it maintains a current ratio of 9.93x, a quick ratio of 9.77x, working capital of $587.98M, a debt-to-equity ratio of 1.84x, a debt ratio of 0.65, an interest coverage ratio of -227.76x, free cash flow of $-225.97M (TTM), and net debt of $100.44M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.60B
- P/E TTM
- -3.31x
- EPS TTM
- $-7.67
- P/B TTM
- 6.48x
- ROE TTM
- -199.04%
- ROA TTM
- -97.39%
- Debt To Equity
- 1.84x
- Free Cash Flow TTM
- $-225.97M
- Net Revenue TTM Growth 1Y
- -93.33%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Zenas BioPharma, Inc. in?
Zenas BioPharma, Inc. (ZBIO) operates in the Pharmaceutical Preparations industry.
What exchange does ZBIO trade on?
Zenas BioPharma, Inc. (ZBIO) trades on the Nasdaq.
Where is Zenas BioPharma, Inc. incorporated?
Zenas BioPharma, Inc. is incorporated in DE.
When was Zenas BioPharma, Inc. (ZBIO)'s most recent SEC filing?
Zenas BioPharma, Inc. (ZBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ZBIO's market cap?
Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $1.60B as of 2026-06-30.
What is ZBIO's EPS (earnings per share)?
Zenas BioPharma, Inc. (ZBIO)'s trailing twelve month EPS is $-7.67 as of 2026-06-30.
What is ZBIO's ROE (return on equity)?
Zenas BioPharma, Inc. (ZBIO)'s trailing twelve month Return on Equity (ROE) is -199.04% as of 2026-06-30.
What is ZBIO's ROA (return on assets)?
Zenas BioPharma, Inc. (ZBIO)'s trailing twelve month Return on Assets (ROA) is -97.39% as of 2026-06-30.
What is ZBIO's ROIC (return on invested capital)?
Zenas BioPharma, Inc. (ZBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -175.01% as of 2026-06-30.
What is ZBIO's EV/EBITDA?
Zenas BioPharma, Inc. (ZBIO)'s trailing twelve month EV/EBITDA is -3.58x as of 2026-06-30.